Pharosyn, a London-based AI infrastructure startup for pharmaceutical commercial decision-making, raised €2.5 million (approximately $2.7M) in what appears to be its first institutional funding round since founding in 2025. The Seed round was led by Moonfire, with participation from Entrepreneurs First, Transpose Platform, and General Advance. The capital will be used to expand the platform and drive adoption across pharma commercial and portfolio strategy teams, where senior directors at top-10 pharmaceutical companies already reportedly use the product. The round is part of a broader trend in 2026 AI/data infrastructure funding for pharma and biotech, which EU-Startups has tracked at roughly €75.3 million across seven comparable rounds to date.